- Home
- SATL vs IMTX Comparison
SATL vs IMTX Comparison
Compare SATL & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- IMTX
- Stock Information
- Founded
- SATL 2010
- IMTX N/A
- Country
- SATL United States
- IMTX Germany
- Employees
- SATL N/A
- IMTX N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SATL Technology
- IMTX Health Care
- Exchange
- SATL Nasdaq
- IMTX Nasdaq
- Market Cap
- SATL 433.8M
- IMTX 514.2M
- IPO Year
- SATL N/A
- IMTX N/A
- Fundamental
- Price
- SATL $3.61
- IMTX $4.32
- Analyst Decision
- SATL
- IMTX Strong Buy
- Analyst Count
- SATL 0
- IMTX 4
- Target Price
- SATL N/A
- IMTX $16.67
- AVG Volume (30 Days)
- SATL 655.1K
- IMTX 837.3K
- Earning Date
- SATL 04-29-2025
- IMTX 05-13-2025
- Dividend Yield
- SATL N/A
- IMTX N/A
- EPS Growth
- SATL N/A
- IMTX N/A
- EPS
- SATL N/A
- IMTX 0.14
- Revenue
- SATL $12,870,000.00
- IMTX $161,336,577.00
- Revenue This Year
- SATL N/A
- IMTX N/A
- Revenue Next Year
- SATL N/A
- IMTX $18.80
- P/E Ratio
- SATL N/A
- IMTX $29.87
- Revenue Growth
- SATL 27.75
- IMTX 188.60
- 52 Week Low
- SATL $0.72
- IMTX $3.30
- 52 Week High
- SATL $5.49
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- SATL 49.29
- IMTX 49.86
- Support Level
- SATL $3.36
- IMTX $4.03
- Resistance Level
- SATL $4.22
- IMTX $4.39
- Average True Range (ATR)
- SATL 0.42
- IMTX 0.36
- MACD
- SATL -0.02
- IMTX 0.06
- Stochastic Oscillator
- SATL 40.76
- IMTX 86.44
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.